Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Acrivon Therapeutics, Inc.(ACRV US)

$1.43-0.032.05%Ext:$1.38-0.053.82%(Market Closed · 00:55:54 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Acrivon Therapeutics, Inc.(ACRV US)

$1.43-0.032.05%Ext:$1.38-0.053.82%(Market Closed · 00:55:54 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees
ACRV US​
Ask AI

Acrivon Therapeutics, Inc. — Company Profile

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Peter Blume-Jensen
Headquarters
Watertown, MA, US
IPO Date
Nov 15, 2022
Employees
75
Website
www.acrivon.com

Key Metrics

Price
$1.99
Market Cap
$85.18M
Revenue (TTM)
$0.00
Net Income (TTM)
$-19042000.00
EPS (TTM)
-0.49
P/E (TTM)
-1.10
P/B (TTM)
0.89
Dividend Yield
0.00%
ROE (TTM)
-19.94%
ROA (TTM)
-17.66%
Operating Margin
0.00%
Beta
1.91

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Website
www.acrivon.com
Location
Watertown, MA, US
Phone617-207-8979
Employees75
CEOPeter Blume-Jensen
Sector
Health Care
Industry
Pharmaceuticals
IPO DateNov 15, 2022

Latest Documents

News

  • Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights16 Nov
  • Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript10 Nov
  • Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB6 Nov
  • Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics4 Nov
  • Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium29 Oct
  • Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 202720 Oct
  • What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock15 Sep
  • Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?3 Sep
  • Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference2 Sep
  • Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer31 Aug
  • Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy24 Aug

Key Stats

Trading

Px/Chg 1D$1.99 / -1.00%
Prev Close$2.13
% of 52Wk H58.99%
Avg Volume668.34K
Beta1.91
Mkt Cap85.18M
FD Mkt Cap89.88M

Float

Shrs Out/Float42.80M / 27.93M
Short Float0.13%
Days to Cover7.58
Stock Repurchased$0.00

Current Valuation

EV53.53M
EV/EBITDA-0.65
EV/Sales0.00
P/B0.89
P/S0.00
FCF Yield-24.13%
ROE-19.94%
ROA-17.66%
Current Ratio8.98

Estimates

P/E-1.10
Est P/E0.00
Est EPS-0.49
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-4.16-8.94-3.10-0.54-3.83-4.38
Price / Sales0.000.000.000.000.000.00
Price / Book Value0.991.631.540.240.650.87
Price / Free Cash Flow-4.46-8.63-4.26-0.63-4.71-4.06
ENTERPRISE VALUE METRICS
Enterprise Value100.6254.1155.97.134.051.8
Enterprise Value / Sales0.000.000.000.000.000.00
Enterprise Value / EBITDA-2.94-7.87-2.60-0.09-1.37-2.78
Enterprise Value / EBIT-2.90-7.78-2.58-0.09-1.35-2.72

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-----
Gross Income—---0.5-1.0-1.4
EBITDA47.6%-16.1-32.3-59.9-79.6-76.5
EBIT48.1%-16.2-32.7-60.4-80.6-77.9
Net Income48%-16.2-31.2-60.4-80.6-77.9
EPS (Diluted)12.5%-1.26-1.42-2.74-2.10-2.02
BALANCE SHEET
Cash & ST Inv4.5%99.6127.8127.5179.5118.6
Total Assets5%106.6181.2138.3196.6129.7
Total Liabilities-39.7%130.410.817.119.817.2
Total Shareholder Equity—-23.8170.5121.2176.8112.5
CASH FLOW
Net Operating Cash Flow46.1%-14.0-30.1-42.6-65.7-63.7
Cap Ex62.7%-0.2-2.2-1.3-2.8-1.7
Free Cash Flow46.4%-14.2-32.3-43.9-68.4-65.3

Enterprise Value Bridge

Millions USD17 Nov '26
Price (As of 17 Nov '26)1.48
Basic Shares42.80
Market Cap63.3
Diluted Shares41.84
Fully Diluted Shares Outstanding41.84
Fully Diluted Market Cap61.9
+Consolidated Debt2.1
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-41.4
−Short-term Investments-48.5
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value24.0

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

ACRV US​
Ask AI

Acrivon Therapeutics, Inc. — Company Profile

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Peter Blume-Jensen
Headquarters
Watertown, MA, US
IPO Date
Nov 15, 2022
Employees
75
Website
www.acrivon.com

Key Metrics

Price
$1.99
Market Cap
$85.18M
Revenue (TTM)
$0.00
Net Income (TTM)
$-19042000.00
EPS (TTM)
-0.49
P/E (TTM)
-1.10
P/B (TTM)
0.89
Dividend Yield
0.00%
ROE (TTM)
-19.94%
ROA (TTM)
-17.66%
Operating Margin
0.00%
Beta
1.91

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Website
www.acrivon.com
Location
Watertown, MA, US
Phone617-207-8979
Employees75
CEOPeter Blume-Jensen
Sector
Health Care
Industry
Pharmaceuticals
IPO DateNov 15, 2022

Latest Documents

News

  • Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights16 Nov
  • Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript10 Nov
  • Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB6 Nov
  • Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics4 Nov
  • Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium29 Oct
  • Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 202720 Oct
  • What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock15 Sep
  • Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?3 Sep
  • Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference2 Sep
  • Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer31 Aug
  • Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy24 Aug

Key Stats

Trading

Px/Chg 1D$1.99 / -1.00%
Prev Close$2.13
% of 52Wk H58.99%
Avg Volume668.34K
Beta1.91
Mkt Cap85.18M
FD Mkt Cap89.88M

Float

Shrs Out/Float42.80M / 27.93M
Short Float0.13%
Days to Cover7.58
Stock Repurchased$0.00

Current Valuation

EV53.53M
EV/EBITDA-0.65
EV/Sales0.00
P/B0.89
P/S0.00
FCF Yield-24.13%
ROE-19.94%
ROA-17.66%
Current Ratio8.98

Estimates

P/E-1.10
Est P/E0.00
Est EPS-0.49
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-4.16-8.94-3.10-0.54-3.83-4.38
Price / Sales0.000.000.000.000.000.00
Price / Book Value0.991.631.540.240.650.87
Price / Free Cash Flow-4.46-8.63-4.26-0.63-4.71-4.06
ENTERPRISE VALUE METRICS
Enterprise Value100.6254.1155.97.134.051.8
Enterprise Value / Sales0.000.000.000.000.000.00
Enterprise Value / EBITDA-2.94-7.87-2.60-0.09-1.37-2.78
Enterprise Value / EBIT-2.90-7.78-2.58-0.09-1.35-2.72

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-----
Gross Income—---0.5-1.0-1.4
EBITDA47.6%-16.1-32.3-59.9-79.6-76.5
EBIT48.1%-16.2-32.7-60.4-80.6-77.9
Net Income48%-16.2-31.2-60.4-80.6-77.9
EPS (Diluted)12.5%-1.26-1.42-2.74-2.10-2.02
BALANCE SHEET
Cash & ST Inv4.5%99.6127.8127.5179.5118.6
Total Assets5%106.6181.2138.3196.6129.7
Total Liabilities-39.7%130.410.817.119.817.2
Total Shareholder Equity—-23.8170.5121.2176.8112.5
CASH FLOW
Net Operating Cash Flow46.1%-14.0-30.1-42.6-65.7-63.7
Cap Ex62.7%-0.2-2.2-1.3-2.8-1.7
Free Cash Flow46.4%-14.2-32.3-43.9-68.4-65.3

Enterprise Value Bridge

Millions USD17 Nov '26
Price (As of 17 Nov '26)1.48
Basic Shares42.80
Market Cap63.3
Diluted Shares41.84
Fully Diluted Shares Outstanding41.84
Fully Diluted Market Cap61.9
+Consolidated Debt2.1
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-41.4
−Short-term Investments-48.5
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value24.0

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US